Progress in Adenoviral Capsid-Display Vaccines
AbstractAdenoviral vectored vaccines against infectious diseases are currently in clinical trials due to their capacity to induce potent antigen-specific B- and T-cell immune responses. Heterologous prime-boost vaccination with adenoviral vector and, for example, adjuvanted protein-based vaccines can further enhance antigen-specific immune responses. Although leading to potent immune responses, these heterologous prime-boost regimens may be complex and impact manufacturing costs limiting efficient implementation. Typically, adenoviral vectors are engineered to genetically encode a transgene in the E1 region and utilize the host cell machinery to express the encoded antigen and thereby induce immune responses. Similarly, adenoviral vectors can be engineered to display foreign immunogenic peptides on the capsid-surface by insertion of antigens in capsid proteins hexon, fiber and protein IX. The ability to use adenoviral vectors as antigen-display particles, with or without using the genetic vaccine function, greatly increases the versatility of the adenoviral vector for vaccine development. This review describes the application of adenoviral capsid antigen-display vaccine vectors by focusing on their distinct advantages and possible limitations in vaccine development. View Full-Text
Share & Cite This Article
Vujadinovic, M.; Vellinga, J. Progress in Adenoviral Capsid-Display Vaccines. Biomedicines 2018, 6, 81.
Vujadinovic M, Vellinga J. Progress in Adenoviral Capsid-Display Vaccines. Biomedicines. 2018; 6(3):81.Chicago/Turabian Style
Vujadinovic, Marija; Vellinga, Jort. 2018. "Progress in Adenoviral Capsid-Display Vaccines." Biomedicines 6, no. 3: 81.
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.